Monitor the upcoming Q3 2026 earnings call for Repligen's updated financial outlook incorporating BioLife. Watch for integration execution and revenue contribution from BioLife's cell therapy consumables business.
Price Chart
Executive Summary
Repligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026. BioLife stockholders received $11.25 cash and 0.1442 shares of Repligen common stock per share. The deal expands Repligen's presence in the cell therapy market with BioLife's biopreservation media portfolio, including CryoStor, which supports 18 commercially approved therapies.
Key Facts
- Acquisition of BioLife Solutions completed on October 6, 2026
- Consideration: $11.25 cash and 0.1442 shares of Repligen common stock per BioLife share
- BioLife's CryoStor portfolio supports 18 commercially approved therapies
- BioLife delisted from Nasdaq; Form 15 deregistration to follow
- Repligen to provide financial impact detail in Q3 2026 earnings call
Financial Impact
Mixed cash-and-stock deal; per-share consideration of $11.25 cash + 0.1442 RGEN shares per BioLife share; total deal value not disclosed
Risk Factors
- Integration risk from merging BioLife's operations and global reach
- Potential dilution from stock consideration component of consideration
- Cell therapy market growth may not meet expectations
- BioLife's customer concentration risk post-acquisition
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-415015 |
| Document: d240327dex991.htm | 0001193125-26-415015 |
| Document: 0001193125-26-415015-index-headers.html | 0001193125-26-415015 |
| Document: 0001193125-26-415015-index.html | 0001193125-26-415015 |
| Document: 0001193125-26-415015.txt | 0001193125-26-415015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $176.93 | awaiting T+60 | — | $175.80 (−0.64%) |
Oct 27, 2026 today | Press Release | $181.38 | awaiting T+60 | — | $175.80 (−3.08%) |
Oct 15, 2026 12d ago | Institutional Cluster | $184.17 | awaiting T+60 | — | $175.80 (−4.54%) |
Oct 7, 2026 20d ago | SC 13G/A | $167.22 | awaiting T+60 | — | $175.80 (+5.13%) |
Oct 6, 2026 21d ago | 8-K | $174.86 | awaiting T+60 | — | $175.80 (+0.54%) |
Oct 6, 2026 21d ago | Press Release | $174.86 | awaiting T+60 | — | $175.80 (+0.54%) |
Aug 24, 2026 9w ago | S-4 | $181.69 | awaiting T+60 | — | $175.80 (−3.24%) |
Jul 28, 2026 13w ago | 8-K | $145.34 $180.01 | ▲ +23.85% | ▲ +19.50% | $175.80 (+20.96%) |
Jul 22, 2026 13w ago | 425 / 8-K | $140.09 $184.17 | ▲ +31.47% | ▲ +28.20% | $175.80 (+25.49%) |
Jul 22, 2026 13w ago | Press Release | $140.09 $184.17 | ▲ +31.47% | ▲ +28.20% | $175.80 (+25.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers